- Home
- HHS vs ITRM Comparison
HHS vs ITRM Comparison
Compare HHS & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | ITRM |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 24.3M |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HHS | ITRM |
|---|---|---|
| Price | $2.31 | $0.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 3.1K | ★ 2.6M |
| Earning Date | 03-17-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.35 | 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,570,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.23 | $0.03 |
| 52 Week High | $5.39 | $1.42 |
Technical Indicators
Market Signals| Indicator | HHS | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 28.54 | 30.25 |
| Support Level | N/A | N/A |
| Resistance Level | $3.03 | $0.39 |
| Average True Range (ATR) | 0.06 | 0.02 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 16.07 | 29.32 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.